13alpha-乙基-2,3,5,6,13a,13b-六氢-1H-吲哚并(3,2,1-去)吡啶并(3,2,1-ij)(1,5)-萘啶-12-羧酸甲氧基甲基酯 | 78101-34-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - Eburnan型生物碱
• 中文名称: 13alpha-乙基-2,3,5,6,13a,13b-六氢-1H-吲哚并(3,2,1-去)吡啶并(3,2,1-ij)(1,5)-萘啶-12-羧酸甲氧基甲基酯
• 英文名称: MR-711
• 英文别名: methylenemethoxyapovincaminate；Methoxymethyl Apovincaminate；methoxymethyl (15S,19S)-15-ethyl-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),16-pentaene-17-carboxylate
• CAS: 78101-34-5
• 化学式: C₂₂H₂₆N₂O₃
• 分子量: 366.46
• InChiKey: YFTYPMACWTZHPH-IRLDBZIGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  43.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  13alpha-乙基-2,3,5,6,13a,13b-六氢-1H-吲哚并(3,2,1-去)吡啶并(3,2,1-ij)(1,5)-萘啶-12-羧酸甲氧基甲基酯 在 盐酸 作用下， 反应 2.0h， 生成 长春乙酯羧酸
  参考文献：
  名称：

  Marzo; Quadro; Stradi, Arzneimittel-Forschung/Drug Research, 1981, vol. 31, # 10, p. 1681 - 1684

  摘要：

  DOI：
• 作为产物：
  描述：

  溴甲基甲基醚 、 potassium apovincaminate 以 丁酮 为溶剂， 以7.8 g的产率得到13alpha-乙基-2,3,5,6,13a,13b-六氢-1H-吲哚并(3,2,1-去)吡啶并(3,2,1-ij)(1,5)-萘啶-12-羧酸甲氧基甲基酯
  参考文献：
  名称：

  Galzigna; Quadro; Saccarello, European Journal of Medicinal Chemistry, 1981, vol. 16, # 2, p. 191 - 192

  摘要：

  DOI：

文献信息

• METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS
  申请人：Yan Chen

  公开号：US20100221340A1

  公开（公告）日：2010-09-02

  Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
• Method and Compositions for Treatment or Prevention of Inflammatory Conditions
  申请人：Yan Chen

  公开号：US20140296273A1

  公开（公告）日：2014-10-02

  Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
• US9241932B2
  申请人：——

  公开号：US9241932B2

  公开（公告）日：2016-01-26
• US9682070B2
  申请人：——

  公开号：US9682070B2

  公开（公告）日：2017-06-20
• [EN] METHOD AND COMPOSITIONS FOR TREATMENT OR PREVENTION OF INFLAMMATORY CONDITIONS<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT OU LA PRÉVENTION D'ÉTATS INFLAMMATOIRES
  申请人：UNIV ROCHESTER

  公开号：WO2009039069A1

  公开（公告）日：2009-03-26

  Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.